Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.68 |
| ▸ | GABRP | O00591 | 2/20 | 0.54 |
| ▸ | GABRD | O14764 | 2/20 | 0.54 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.54 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.54 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.54 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.54 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.54 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.54 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.54 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.54 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.54 |
| ▸ | GABRE | P78334 | 2/20 | 0.54 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.54 |
| ▸ | GABRG1 | Q8N1C3 | 2/20 | 0.54 |
| ▸ | GABRG3 | Q99928 | 2/20 | 0.54 |
| ▸ | GABRQ | Q9UN88 | 2/20 | 0.54 |
| ▸ | TET2 | Q6N021 | 3/20 | 0.44 |
| ▸ | KDM4A | O75164 | 2/20 | 0.44 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14197461 | 1.00 | CYP1A2 (0.68) | CYP1A2GABRPGABRDGABRA1GABRB1 | |
| SCHEMBL12658700 | 1.00 | CYP1A2 (0.68) | CYP1A2GABRPGABRDGABRA1GABRB1 | |
| SCHEMBL10068076 | 0.85 | CYP1A2 (0.50) | CYP1A2GABRPGABRDGABRA1GABRB1 | |
| SCHEMBL2348647 | 0.85 | CYP1A2 (0.50) | CYP1A2GABRPGABRDGABRA1GABRB1 | |
| SCHEMBL999059 | 0.83 | FFAR4 (0.53) | CYP1A2LMNAENPEP | |
| SCHEMBL559468 | 0.81 | FFAR4 (0.57) | LMNA | |
| SCHEMBL14093813 | 0.81 | FFAR4 (0.57) | LMNA | |
| SCHEMBL304217 | 0.81 | FFAR4 (0.57) | LMNA | |
| SCHEMBL28750 | 0.81 | CYP1A2 (1.00) | CYP1A2GABRPGABRDGABRA1GABRB1 | |
| SCHEMBL791764 | 0.81 | CYP1A2 (1.00) | CYP1A2GABRPGABRDGABRA1GABRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9422224-B2 | Methods of treatment using a BCAT1 inhibitor | ERGON PHARMACEUTICALS LLC (US) | 2016-08-23 | — | — | US | claimed |
| US-20140128467-A1 | METHODS OF TREATMENT USING A BCAT1 INHIBITOR | ERGON PHARMACEUTICALS LLC (US) | 2014-05-08 | — | — | US | claimed |
| EP-2717869-A2 | METHODS OF TREATMENT USING A BCAT1 INHIBITOR | Ergon Pharmaceuticals LLC (US) | 2014-04-16 | — | — | EP | claimed |
| WO-2012173987-A2 | METHODS OF TREATMENT USING A BCAT1 INHIBITOR | ERGON PHARMACEUTICALS LLC (US) | 2012-12-20 | — | — | WO | claimed |
| US-20020026047-A1 | Calixpyrroles, calixpyridinopyrroles, and calixpyridines | BOARD OF REGENTS, THE | 2002-02-28 | — | — | US | claimed |
| JP-2000511880-A | — | — | 2000-09-12 | — | — | JP | claimed |
| EP-0891364-A1 | CALIXPYRROLES, CALIXPYRIDINOPYRROLES AND CALIXPYRIDINES | THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1999-01-20 | — | — | EP | claimed |
| WO-1997037995-A1 | CALIXPYRROLES, CALIXPYRIDINOPYRROLES AND CALIXPYRIDINES | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1997-10-16 | — | — | WO | claimed |
| US-4611033-A | Process for stabilizing a poly(aryl ether ketone) | UNION CARBIDE CORPORATION (US) | 1986-09-09 | — | — | US | claimed |
| JP-2000131-A | — | — | None | — | — | JP | disclosed |
| WO-2025003023-A1 | METHOD FOR PRODUCING A CARBOXYLIC ACID | EVONIK OPERATIONS GMBH (DE) | 2025-01-02 | — | — | WO | disclosed |
| CN-112661639-A | Synthesis method of 4-acetylbutyrate compound | 浙江工业大学 | 2021-04-16 | — | — | CN | disclosed |
| US-9493512-B2 | Solution phase processes for the manufacture of macrocyclic depsipeptides and new intermediates | NOVARTIS AG (CH) | 2016-11-15 | — | — | US | disclosed |
| US-9464048-B2 | 5-oxo-ETE receptor antagonist compounds | FLORIDA INSTITUTE OF TECHNOLOGY (US) | 2016-10-11 | — | — | US | disclosed |
| EP-0080240-A1 | Process for the preparation of a lactam | STAMICARBON B.V. (NL) | 1983-06-01 | — | — | EP | disclosed |
| EP-0075372-A1 | Process for the preparation of a lactam | STAMICARBON B.V. (NL) | 1983-03-30 | — | — | EP | disclosed |
| US-4291170-A | A,B-UNSATURATED ESTER, KETONE, PRIMARY AMINE OR SCHIFF BASE, ACID | STAMICARBON, B.V. (NL) | 1981-09-22 | — | — | US | disclosed |
| US-4154965-A | Process for the preparation of resorcinol or alkylsubstituted derivatives thereof | STAMICARBON, B.V. (NL) | 1979-05-15 | — | — | US | disclosed |
| US-4072660-A | FROM A 4-OXO-CARBOXYLIC ACID ESTER OR DELTA-ENOL-LACTONE AND STRONG BASE IN GLYCOL DIALKYL ETHER SOLVENT | HOECHST AKTIENGESELLSCHAFT (DT) | 1978-02-07 | — | — | US | disclosed |
| US-4041049-A | CATALYTIC DEHYDRATION AND CYCLIZATION AND CYCLIZATION OF 4-OXOCARBOXYLIC ACIDS | HOECHST AKTIENGESELLSCHAFT (DT) | 1977-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140128467-A1 | METHODS OF TREATMENT USING A BCAT1 INHIBITOR | BCAT1, BCAT2, TPT1 | CYP1A2 4335/4885GABRP 3182/4885GABRD 3294/4885 |
| US-20020026047-A1 | Calixpyrroles, calixpyridinopyrroles, and calixpyridines | CALD1, DAP3, CALR | CYP1A2 3644/4885GABRP 1383/4885GABRD 2025/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.